Welfare barriers and levers for improvement in organic and low-input outdoor pig and poultry production systems

International audienceThe PPILOW project aims to co-construct innovations to improve Poultry and Pig Welfare in Low-input outdoor and Organic farming systems through a multi-actor approach. Its first step was to sum up animal welfare challenges observed in these systems and levers of improvement, from a review of literature data and research projects. Data were completed with information from key informants of the supply chains of poultry meat, eggs and pork in Italy, France, the United Kingdom and Finland. The interviews indicated that the main issues in poultry were: feeding, biosecurity, lack of range use and range management, feather pecking, weather, regulation, flock size or density, predation, bone fractures, lack of robustness, parasitism, pododermatitis, arthrosis, nervousness, water quality, catching and time spent by farmers. The main issues in pig were: feeding, tail biting, mortality, weather, predation, lack of robustness, lack of range use, castration, animal aggressiveness and competition, water quality, range management, human welfare, biosecurity issues, flock size or density, parasitism, insolation burns, joint abnormalities, parturition in freedom and pollution. This information has implemented a participatory approach for proposing welfare-improvement levers. Some issues and potential solutions were included in PPILOW experiments (phytotherapy against parasitism, involvement of animal personality in range use, rearing of entire pig males, genetic selection for reduced piglet mortality, improved farrowing huts for sows and piglets reared on range, avoiding feather pecking in laying hens with intact beaks, avoiding the killing of day-old male chicks etc.), and solution costs evaluated. The results will provide a combination of practical solutions for welfare improvement in Europe. The PPILOW project has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement N°816172

Welfare barriers and levers for improvement in organic and low-input outdoor pig and poultry production systems

International audienceThe PPILOW project aims to co-construct innovations to improve Poultry and Pig Welfare in Low-input outdoor and Organic farming systems through a multi-actor approach. Its first step was to sum up animal welfare challenges observed in these systems and levers of improvement, from a review of literature data and research projects. Data were completed with information from key informants of the supply chains of poultry meat, eggs and pork in Italy, France, the United Kingdom and Finland. The interviews indicated that the main issues in poultry were: feeding, biosecurity, lack of range use and range management, feather pecking, weather, regulation, flock size or density, predation, bone fractures, lack of robustness, parasitism, pododermatitis, arthrosis, nervousness, water quality, catching and time spent by farmers. The main issues in pig were: feeding, tail biting, mortality, weather, predation, lack of robustness, lack of range use, castration, animal aggressiveness and competition, water quality, range management, human welfare, biosecurity issues, flock size or density, parasitism, insolation burns, joint abnormalities, parturition in freedom and pollution. This information has implemented a participatory approach for proposing welfare-improvement levers. Some issues and potential solutions were included in PPILOW experiments (phytotherapy against parasitism, involvement of animal personality in range use, rearing of entire pig males, genetic selection for reduced piglet mortality, improved farrowing huts for sows and piglets reared on range, avoiding feather pecking in laying hens with intact beaks, avoiding the killing of day-old male chicks etc.), and solution costs evaluated. The results will provide a combination of practical solutions for welfare improvement in Europe. The PPILOW project has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement N°816172

Welfare barriers and levers for improvement in organic and low-input outdoor pig and poultry production systems

International audienceThe PPILOW project aims to co-construct innovations to improve Poultry and Pig Welfare in Low-input outdoor and Organic farming systems through a multi-actor approach. Its first step was to sum up animal welfare challenges observed in these systems and levers of improvement, from a review of literature data and research projects. Data were completed with information from key informants of the supply chains of poultry meat, eggs and pork in Italy, France, the United Kingdom and Finland. The interviews indicated that the main issues in poultry were: feeding, biosecurity, lack of range use and range management, feather pecking, weather, regulation, flock size or density, predation, bone fractures, lack of robustness, parasitism, pododermatitis, arthrosis, nervousness, water quality, catching and time spent by farmers. The main issues in pig were: feeding, tail biting, mortality, weather, predation, lack of robustness, lack of range use, castration, animal aggressiveness and competition, water quality, range management, human welfare, biosecurity issues, flock size or density, parasitism, insolation burns, joint abnormalities, parturition in freedom and pollution. This information has implemented a participatory approach for proposing welfare-improvement levers. Some issues and potential solutions were included in PPILOW experiments (phytotherapy against parasitism, involvement of animal personality in range use, rearing of entire pig males, genetic selection for reduced piglet mortality, improved farrowing huts for sows and piglets reared on range, avoiding feather pecking in laying hens with intact beaks, avoiding the killing of day-old male chicks etc.), and solution costs evaluated. The results will provide a combination of practical solutions for welfare improvement in Europe. The PPILOW project has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement N°816172

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

International audienceBackground: Various observations have suggested that the course of COVID-19 might be less favourable in patients with inflammatory rheumatic and musculoskeletal diseases receiving rituximab compared with those not receiving rituximab. We aimed to investigate whether treatment with rituximab is associated with severe COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases.Methods: In this cohort study, we analysed data from the French RMD COVID-19 cohort, which included patients aged 18 years or older with inflammatory rheumatic and musculoskeletal diseases and highly suspected or confirmed COVID-19. The primary endpoint was the severity of COVID-19 in patients treated with rituximab (rituximab group) compared with patients who did not receive rituximab (no rituximab group). Severe disease was defined as that requiring admission to an intensive care unit or leading to death. Secondary objectives were to analyse deaths and duration of hospital stay. The inverse probability of treatment weighting propensity score method was used to adjust for potential confounding factors (age, sex, arterial hypertension, diabetes, smoking status, body-mass index, interstitial lung disease, cardiovascular diseases, cancer, corticosteroid use, chronic renal failure, and the underlying disease [rheumatoid arthritis vs others]). Odds ratios and hazard ratios and their 95% CIs were calculated as effect size, by dividing the two population mean differences by their SD. This study is registered with ClinicalTrials.gov, NCT04353609.Findings: Between April 15, 2020, and Nov 20, 2020, data were collected for 1090 patients (mean age 55·2 years [SD 16·4]); 734 (67%) were female and 356 (33%) were male. Of the 1090 patients, 137 (13%) developed severe COVID-19 and 89 (8%) died. After adjusting for potential confounding factors, severe disease was observed more frequently (effect size 3·26, 95% CI 1·66-6·40, p=0·0006) and the duration of hospital stay was markedly longer (0·62, 0·46-0·85, p=0·0024) in the 63 patients in the rituximab group than in the 1027 patients in the no rituximab group. 13 (21%) of 63 patients in the rituximab group died compared with 76 (7%) of 1027 patients in the no rituximab group, but the adjusted risk of death was not significantly increased in the rituximab group (effect size 1·32, 95% CI 0·55-3·19, p=0·53).Interpretation: Rituximab therapy is associated with more severe COVID-19. Rituximab will have to be prescribed with particular caution in patients with inflammatory rheumatic and musculoskeletal diseases